UK-based life sciences company ProBiotix Health has signed a long-term agreement with South Korea’s TopHealth to distribute its probiotic products. The deal grants TopHealth exclusive rights to sell ProBiotix’s CholBiome® brand, private-label solutions under YourBiotix, and products under TopHealth’s own consumer brand.
South Korea’s probiotics supplement market, valued at £350 million in 2023, is projected to reach £870 million by 2030. The partnership leverages TopHealth’s expertise in consumer health and its strong presence in the influencer-driven marketing space to expand ProBiotix’s footprint in this high-growth market.
